Analysts’ Viewpoint
The global fecal calprotectin test market is expected to witness significant growth in the next few years due to rise in prevalence of inflammatory bowel disease (IBD) and gastrointestinal disorders. Fecal calprotectin test is most commonly used in adult patients due to high incidence rate of inflammatory bowel disease (IBD) and colorectal cancer among these patients. Increase in awareness among patients and healthcare professionals about the benefits of early diagnosis and treatment is expected to drive global fecal calprotectin test market growth.
Development of more accurate and low cost fecal calprotectin tests offers lucrative opportunities to market players. Companies are focusing on developing cost-efficient and more precise tests in order to increase market share and revenue. However, high cost of tests and lack of reimbursement policies in some regions are likely to hamper market growth.
The stool calprotectin test is a diagnostic tool used to measure the level of calprotectin in the stool. Calprotectin is a protein released by white blood cells in the intestines during inflammation, making it a useful marker for various gastrointestinal disorders, particularly inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis.
The stool calprotectin test is non-invasive and provides valuable information to healthcare professionals in assessing the severity of intestinal inflammation, monitoring disease activity, and determining treatment strategies. It is often used in combination with other clinical evaluations and imaging techniques to aid in the diagnosis and management of gastrointestinal conditions.
The two types of fecal calprotectin test available in the market are quantitative and qualitative. The quantitative test measures the exact amount of calprotectin in the stool, while the qualitative test provides a positive or negative result based on a predetermined threshold.
The quantitative test is more accurate and provides a more precise measurement of calprotectin levels, but it is also more expensive. The qualitative test is less expensive and provides a quick and easy result, but it is less accurate and may lead to false positives or false negatives.
Fecal calprotectin normal range is 10 to 50 or 60 μg/mg. The treatment for high calprotectin levels includes anti-inflammatory medicine, which helps to reduce inflammation in diseases such as IBD, colorectal cancer, and others.
Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gastrointestinal tract that includes Crohn's disease and ulcerative colitis. Prevalence of IBD is increasing globally, particularly in developed countries.
According to the Centers for Disease Control and Prevention (CDC), around 3 million adults in the U.S. have been diagnosed with IBD. In Europe, the prevalence of IBD is estimated to be 0.3% to 0.5% of the total population.
Several factors contribute to the increasing prevalence of IBD, including:
Rise in prevalence of IBD is driving demand for accurate and reliable diagnostic tools such as fecal calprotectin testing. Early detection and treatment of IBD can help improve patient outcomes and reduce the risk of complications. Hence, demand for non-invasive diagnostic tests such as fecal calprotectin testing is high.
Non-invasiveness of fecal calprotectin testing is a major driver of the global fecal calprotectin test market. Fecal calprotectin testing is a non-invasive diagnostic tool used to evaluate gastrointestinal inflammation and is increasingly being used in the diagnosis and management of inflammatory bowel disease (IBD) and other gastrointestinal disorders.
Unlike other diagnostic tests, such as colonoscopy or biopsy, fecal calprotectin testing does not require insertion of any devices or instruments into the body. Instead, patients provide a stool sample, which is analyzed in a laboratory to measure the level of calprotectin in the stool. This non-invasive nature of fecal calprotectin testing can be particularly appealing to patients who could be hesitant to undergo more invasive diagnostic procedures.
Non-invasiveness of fecal calprotectin testing also makes it a convenient diagnostic tool for healthcare providers. Fecal calprotectin testing can be performed quickly and easily in a clinical setting, and the results are typically available within a few days. This convenience and ease of use could help to encourage more widespread adoption of fecal calprotectin testing, which is likely to drive the fecal calprotectin test market size.
In terms of patient type, the adults segment is anticipated to account for the largest global fecal calprotectin test market share during the forecast period. This can be ascribed to increase in demand for fecal calprotectin testing among adult patients. According to the National Health Service, people of any age can get IBD, but it is usually diagnosed in patients aged between 15 and 40.
Increase in number of adults suffering from gastrointestinal disorders is likely to drive the segment during the forecast period. According to a survey conducted by the Sahlgrenska Academy at the University of Gothenburg in 2020, nearly 40% of adults were suffering from a functional gastrointestinal disorder.
Functional gastrointestinal disorders represent a series of chronic disorders in the gastrointestinal tract that often include severe symptoms, including heartburn, acid reflux, and dyspepsia in the upper gastrointestinal tract and chronic constipation, abdominal distention or bloating, and irritable bowel syndrome in the lower gastrointestinal tract.
Based on assay type, the enzyme linked immunosorbent assay (ELISA) segment dominated the global fecal calprotectin test market in 2022. The ELISA test for fecal calprotectin is highly accurate and can detect levels as low as 15-20 μg/g of stool. It is a non-invasive diagnostic tool that is less costly and less time-consuming than more invasive diagnostic procedures such as endoscopy or colonoscopy.
The ELISA test for fecal calprotectin is particularly useful for the diagnosis and monitoring of inflammatory bowel disease (IBD) and can also be used to distinguish between IBD and non-IBD conditions with similar symptoms, such as irritable bowel syndrome (IBS).
In terms of indication, the inflammatory bowel disease segment accounted for leading share of the global market in 2022. Fecal calprotectin test is major inflammatory bowel disease test used for diseases diagnosis.
Fecal calprotectin test is primarily used in the diagnosis and monitoring of inflammatory bowel disease (IBD), which typically affects adults. IBD, including Crohn's disease and ulcerative colitis, is a chronic condition that causes inflammation in the gut, leading to symptoms such as abdominal pain, diarrhea, and rectal bleeding. Fecal calprotectin test is also referred as GI inflammation test.
Fecal calprotectin test helps to distinguish between IBD and IBS. Increase in number of patients suffering from inflammatory bowel disease is likely to drive the segment. According to the European Federation of Crohn's & Ulcerative Colitis Associations (EFCCA), there are 10 million people globally living with IBD. However, the number could be higher, if the same prevalence of 1% or more that is true in the U.K. and the U.S. applies to most other western countries.
Based on end-user, the hospitals segment dominated the global fecal calprotectin test market in 2022. Hospitals are one of the primary end-users of fecal calprotectin tests, which are used for the diagnosis and monitoring of patients with inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis.
Presence of large, specialized hospitals equipped with advanced health care infrastructure and specialist professionals for consulting boosts patient preference for hospitals. Availability of a wide range of services in hospital settings is likely to propel the segment during the forecast period.
Europe is a major market for fecal calprotectin tests. This can be ascribed to high prevalence of IBDs, such as Crohn's and ulcerative colitis; availability of advanced healthcare infrastructure & facilities; and presence of several key market players.
Germany dominated the market in Europe in 2022 owing to factors such as large number of IBD patients, high adoption of new technologically advanced products, significant health care expenditure, early availability of advanced technologies, and increase in research activities across the country.
Asia Pacific is anticipated to be the fastest growing region for fecal calprotectin test during the forecast period. The market in the region is anticipated to expand at a high CAGR from 2022 to 2031 due to large patient base in countries such as India and China and rise in awareness about IBD and colorectal cancer.
The global fecal calprotectin test market is fragmented, with the presence of large number of leading players. Manufactures in calprotectin test are investing significantly in research & development, primarily to develop innovative fecal calprotectin test. Expansion of product portfolio and mergers & acquisitions are the key strategies adopted by the key players in the market.
Abbexa, ALPCO, Alpha Laboratories, Biomerica, BÜHLMANN Laboratories AG, DRG INSTRUMENTS GMBH, EagleBio, Epitope Diagnostics, Inc., OPERON, S.A., R-Biopharm AG, Svar Life Science, Thermo Fisher Scientific, Inc., Werfen, SENTINEL CH. SpA, Diazyme Laboratories, Inc., and DiAgam are the key players operating in the global market.
The fecal calprotectin test industry research report profiles key players based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
| Attribute | Detail |
|---|---|
|
Size Value in 2022 |
US$ 126.9 Mn |
|
Forecast (Value) in 2031 |
More than US$ 355.8 Mn |
|
Growth Rate (CAGR) |
10.7% |
|
Forecast Period |
2023-2031 |
|
Historical Data Available for |
2017-2021 |
|
Quantitative Units |
US$ Mn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global industry was valued at US$ 126.9 Mn in 2022
It is projected to reach more than US$ 355.8 Mn by 2031
The industry is anticipated to expand at a CAGR of 10.7% from 2023 to 2031
Rise in prevalence of inflammatory bowel disease (IBD) and non-invasive nature of fecal calprotectin testing are driving the market
Europe is projected to account for major market share during the forecast period
Abbexa, ALPCO, Alpha Laboratories, Biomerica, BÜHLMANN Laboratories AG, DRG Instruments GmbH, EagleBio, Epitope Diagnostics, Inc., OPERON, S.A., R-Biopharm AG, Svar Life Science, Thermo Fisher Scientific, Inc., Werfen, SENTINEL CH. SpA, Diazyme Laboratories Inc., and DiAgam are the prominent players in the market
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Fecal Calprotectin Test Market
4. Market Overview
4.1. Introduction
4.1.1. Patient Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Fecal Calprotectin Test Market Analysis and Forecast, 2017-2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Technological Advancement
5.2. Diseases Epidemiology
5.3. Regulatory Scenario
5.4. Pricing Analysis
5.5. COVID-19 Impact Analysis
6. Global Fecal Calprotectin Test Market Analysis and Forecast, by Patient Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Patient Type, 2017-2031
6.3.1. Adult
6.3.2. Pediatric
6.4. Market Attractiveness Analysis, by Patient Type
7. Global Fecal Calprotectin Test Market Analysis and Forecast, by Assay Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Assay Type, 2017-2031
7.3.1. ELISA (Enzyme linked Immunosorbent Assay)
7.3.2. Enzyme Fluoroimmunoassay
7.3.3. Quantitative Immune-chromatography
7.4. Market Attractiveness Analysis, by Assay Type
8. Global Fecal Calprotectin Test Market Analysis and Forecast, by Indication
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Indication, 2017-2031
8.3.1. Inflammatory Bowel Disease
8.3.2. Colorectal Cancer
8.3.3. Celiac Disease
8.4. Market Attractiveness Analysis, by Indication
9. Global Fecal Calprotectin Test Market Analysis and Forecast, by End-user
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by End-user, 2017-2031
9.3.1. Hospitals
9.3.2. Diagnostic Laboratories
9.3.3. Academic & Research Institutes
9.4. Market Attractiveness Analysis, by End-user
10. Global Fecal Calprotectin Test Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness Analysis, by Region
11. North America Fecal Calprotectin Test Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Patient Type, 2017-2031
11.2.1. Adult
11.2.2. Pediatric
11.3. Market Value Forecast, by Assay Type, 2017-2031
11.3.1. ELISA (Enzyme linked Immunosorbent Assay)
11.3.2. Enzyme Fluoroimmunoassay
11.3.3. Quantitative Immune-chromatography
11.4. Market Value Forecast, by Indication, 2017-2031
11.4.1. Inflammatory Bowel Disease
11.4.2. Colorectal Cancer
11.4.3. Celiac Disease
11.5. Market Value Forecast, by End-user, 2017-2031
11.5.1. Hospitals
11.5.2. Diagnostic Laboratories
11.5.3. Academic & Research Institutes
11.6. Market Value Forecast, by Country, 2017-2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Patient Type
11.7.2. By Assay Type
11.7.3. By Indication
11.7.4. By End-user
11.7.5. By Country
12. Europe Fecal Calprotectin Test Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Patient Type, 2017-2031
12.2.1. Adult
12.2.2. Pediatric
12.3. Market Value Forecast, by Assay Type, 2017-2031
12.3.1. ELISA (Enzyme linked Immunosorbent Assay)
12.3.2. Enzyme Fluoroimmunoassay
12.3.3. Quantitative Immune-chromatography
12.4. Market Value Forecast, by Indication, 2017-2031
12.4.1. Inflammatory Bowel Disease
12.4.2. Colorectal Cancer
12.4.3. Celiac Disease
12.5. Market Value Forecast, by End-user, 2017-2031
12.5.1. Hospitals
12.5.2. Diagnostic Laboratories
12.5.3. Academic & Research Institutes
12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Italy
12.6.5. Spain
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Patient Type
12.7.2. By Assay Type
12.7.3. By Indication
12.7.4. By End-user
12.7.5. By Country/Sub-region
13. Asia Pacific Fecal Calprotectin Test Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Patient Type, 2017-2031
13.2.1. Adult
13.2.2. Pediatric
13.3. Market Value Forecast, by Assay Type, 2017-2031
13.3.1. ELISA (Enzyme linked Immunosorbent Assay)
13.3.2. Enzyme Fluoroimmunoassay
13.3.3. Quantitative Immune-chromatography
13.4. Market Value Forecast, by Indication, 2017-2031
13.4.1. Inflammatory Bowel Disease
13.4.2. Colorectal Cancer
13.4.3. Celiac Disease
13.5. Market Value Forecast, by End-user, 2017-2031
13.5.1. Hospitals
13.5.2. Diagnostic Laboratories
13.5.3. Academic & Research Institutes
13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Patient Type
13.7.2. By Assay Type
13.7.3. By Indication
13.7.4. By End-user
13.7.5. By Country/Sub-region
14. Latin America Fecal Calprotectin Test Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Patient Type, 2017-2031
14.2.1. Adult
14.2.2. Pediatric
14.3. Market Value Forecast, by Assay Type, 2017-2031
14.3.1. ELISA (Enzyme linked Immunosorbent Assay)
14.3.2. Enzyme Fluoroimmunoassay
14.3.3. Quantitative Immune-chromatography
14.4. Market Value Forecast, by Indication, 2017-2031
14.4.1. Inflammatory Bowel Disease
14.4.2. Colorectal Cancer
14.4.3. Celiac Disease
14.5. Market Value Forecast, by End-user, 2017-2031
14.5.1. Hospitals
14.5.2. Diagnostic Laboratories
14.5.3. Academic & Research Institutes
14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Patient Type
14.7.2. By Assay Type
14.7.3. By Indication
14.7.4. By End-user
14.7.5. By Country/Sub-region
15. Middle East & Africa Fecal Calprotectin Test Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Patient Type, 2017-2031
15.2.1. Adult
15.2.2. Pediatric
15.3. Market Value Forecast, by Assay Type, 2017-2031
15.3.1. ELISA (Enzyme linked Immunosorbent Assay)
15.3.2. Enzyme Fluoroimmunoassay
15.3.3. Quantitative Immune-chromatography
15.4. Market Value Forecast, by Indication, 2017-2031
15.4.1. Inflammatory Bowel Disease
15.4.2. Colorectal Cancer
15.4.3. Celiac Disease
15.5. Market Value Forecast, by End-user, 2017-2031
15.5.1. Hospitals
15.5.2. Diagnostic Laboratories
15.5.3. Academic & Research Institutes
15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Patient Type
15.7.2. By Assay Type
15.7.3. By Indication
15.7.4. By End-user
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competitive Matrix (by tier and size of companies)
16.2. Market Share Analysis, by Company (2022)
16.3. Company Profiles
16.3.1. Abbexa
16.3.1.1. Company Overview
16.3.1.2. Drug Class Portfolio
16.3.1.3. SWOT Analysis
16.3.1.4. Financial Overview
16.3.1.5. Strategic Overview
16.3.2. ALPCO
16.3.2.1. Company Overview
16.3.2.2. Drug Class Portfolio
16.3.2.3. SWOT Analysis
16.3.2.4. Financial Overview
16.3.2.5. Strategic Overview
16.3.3. Alpha Laboratories
16.3.3.1. Company Overview
16.3.3.2. Drug Class Portfolio
16.3.3.3. SWOT Analysis
16.3.3.4. Financial Overview
16.3.3.5. Strategic Overview
16.3.4. Biomerica
16.3.4.1. Company Overview
16.3.4.2. Drug Class Portfolio
16.3.4.3. SWOT Analysis
16.3.4.4. Financial Overview
16.3.4.5. Strategic Overview
16.3.5. BÜHLMANN Laboratories AG
16.3.5.1. Company Overview
16.3.5.2. Drug Class Portfolio
16.3.5.3. SWOT Analysis
16.3.5.4. Financial Overview
16.3.5.5. Strategic Overview
16.3.6. DRG Instruments GmbH
16.3.6.1. Company Overview
16.3.6.2. Drug Class Portfolio
16.3.6.3. SWOT Analysis
16.3.6.4. Financial Overview
16.3.6.5. Strategic Overview
16.3.7. EagleBio
16.3.7.1. Company Overview
16.3.7.2. Drug Class Portfolio
16.3.7.3. SWOT Analysis
16.3.7.4. Financial Overview
16.3.7.5. Strategic Overview
16.3.8. Epitope Diagnostics, Inc.
16.3.8.1. Company Overview
16.3.8.2. Drug Class Portfolio
16.3.8.3. SWOT Analysis
16.3.8.4. Financial Overview
16.3.8.5. Strategic Overview
16.3.9. OPERON, S.A.
16.3.9.1. Company Overview
16.3.9.2. Drug Class Portfolio
16.3.9.3. SWOT Analysis
16.3.9.4. Financial Overview
16.3.9.5. Strategic Overview
16.3.10. R-Biopharm AG
16.3.10.1. Company Overview
16.3.10.2. Drug Class Portfolio
16.3.10.3. SWOT Analysis
16.3.10.4. Financial Overview
16.3.10.5. Strategic Overview
16.3.11. Svar Life Science
16.3.11.1. Company Overview
16.3.11.2. Drug Class Portfolio
16.3.11.3. SWOT Analysis
16.3.11.4. Financial Overview
16.3.11.5. Strategic Overview
16.3.12. Thermo Fisher Scientific, Inc.
16.3.12.1. Company Overview
16.3.12.2. Drug Class Portfolio
16.3.12.3. SWOT Analysis
16.3.12.4. Financial Overview
16.3.12.5. Strategic Overview
16.3.13. Werfen
16.3.13.1. Company Overview
16.3.13.2. Drug Class Portfolio
16.3.13.3. SWOT Analysis
16.3.13.4. Financial Overview
16.3.13.5. Strategic Overview
16.3.14. SENTINEL CH. SpA
16.3.14.1. Company Overview
16.3.14.2. Drug Class Portfolio
16.3.14.3. SWOT Analysis
16.3.14.4. Financial Overview
16.3.14.5. Strategic Overview
16.3.15. Diazyme Laboratories, Inc.
16.3.15.1. Company Overview
16.3.15.2. Drug Class Portfolio
16.3.15.3. SWOT Analysis
16.3.15.4. Financial Overview
16.3.15.5. Strategic Overview
16.3.16. DiAgam
16.3.16.1. Company Overview
16.3.16.2. Drug Class Portfolio
16.3.16.3. SWOT Analysis
16.3.16.4. Financial Overview
16.3.16.5. Strategic Overview
List of Tables
Table 01: Global Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Patient Type, 2017-2031
Table 02: Global Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Assay Type, 2017-2031
Table 03: Global Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 04: Global Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 05: Global Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Region, 2017-2031
Table 06: North America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 07: North America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Patient Type, 2017-2031
Table 08: North America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Assay Type, 2017-2031
Table 09: North America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 10: North America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 11: Europe Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 12: Europe Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Patient Type, 2017-2031
Table 13: Europe Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Assay Type, 2017-2031
Table 14: Europe Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 15: Europe Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 16: Asia Pacific Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 17: Asia Pacific Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Patient Type, 2017-2031
Table 18: Asia Pacific Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Assay Type, 2017-2031
Table 19: Asia Pacific Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 20: Asia Pacific Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 21: Latin America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 22: Latin America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Patient Type, 2017-2031
Table 23: Latin America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Assay Type, 2017-2031
Table 24: Latin America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 25: Latin America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 26: Middle East & Africa Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 27: Middle East & Africa Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
Table 28: Middle East & Africa Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Assay Type, 2017-2031
Table 29: Middle East & Africa Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 30: Middle East & Africa Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by End-user, 2017-2031
List of Figures
Figure 01: Global Fecal Calprotectin Test Market Value (US$ Mn) Forecast, 2017-2031
Figure 02: Global Fecal Calprotectin Test Market Value Share, by Patient Type, 2022
Figure 03: Global Fecal Calprotectin Test Market Value Share, by Assay Type, 2022
Figure 04: Global Fecal Calprotectin Test Market Value Share, by Indication, 2022
Figure 05: Global Fecal Calprotectin Test Market Value Share, by End-user, 2022
Figure 06: Global Fecal Calprotectin Test Market Value Share, by Region, 2022
Figure 07: Global Fecal Calprotectin Test Market Value Share Analysis, by Patient Type, 2022 and 2031
Figure 08: Global Fecal Calprotectin Test Market (US$ Mn), by Adult, 2017-2031
Figure 09 Global Fecal Calprotectin Test Market (US$ Mn), by Pediatric, 2017-2031
Figure 10: Global Fecal Calprotectin Test Market Attractiveness Analysis, by Patient Type, 2023-2031
Figure 11: Global Fecal Calprotectin Test Market Value Share Analysis, by Assay Type, 2022 and 2031
Figure 12: Global Fecal Calprotectin Test Market (US$ Mn), by ELISA (Enzyme linked Immunosorbent Assay), 2017-2031
Figure 13 Global Fecal Calprotectin Test Market (US$ Mn), by Enzyme Fluoroimmunoassay, 2017-2031
Figure 14: Global Fecal Calprotectin Test Market (US$ Mn), by Quantitative Immune-chromatography, 2017-2031
Figure 15: Global Fecal Calprotectin Test Market Attractiveness Analysis, by Assay Type, 2023-2031
Figure 16: Global Fecal Calprotectin Test Market Value Share Analysis, by Indication, 2022 and 2031
Figure 17: Global Fecal Calprotectin Test Market (US$ Mn), by Inflammatory Bowel Disease, 2017-2031
Figure 18: Global Fecal Calprotectin Test Market (US$ Mn), by Colorectal Cancer, 2017-2031
Figure 19: Global Fecal Calprotectin Test Market (US$ Mn), by Celiac Disease, 2017-2031
Figure 20: Global Fecal Calprotectin Test Market Attractiveness Analysis, by Indication, 2023-2031
Figure 21: Global Fecal Calprotectin Test Market Value Share Analysis, by End-user, 2022 and 2031
Figure 22: Global Fecal Calprotectin Test Market (US$ Mn), by Hospitals, 2017-2031
Figure 23: Global Fecal Calprotectin Test Market (US$ Mn), by Diagnostic Laboratories, 2017-2031
Figure 24: Global Fecal Calprotectin Test Market (US$ Mn), by Academic & Research Institutes, 2017-2031
Figure 25: Global Fecal Calprotectin Test Market Attractiveness Analysis, by End-user, 2023-2031
Figure 26: Global Fecal Calprotectin Test Market Value Share Analysis, by Region, 2022 and 2031
Figure 27: Global Fecal Calprotectin Test Market Attractiveness Analysis, by Region, 2023-2031
Figure 28: North America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, 2017-2031
Figure 29: North America Fecal Calprotectin Test Market Value Share Analysis, by Country, 2022 and 2031
Figure 30: North America Fecal Calprotectin Test Market Attractiveness Analysis, by Country, 2023-2031
Figure 31: North America Fecal Calprotectin Test Market Value Share Analysis, by Patient Type, 2022 and 2031
Figure 32: North America Fecal Calprotectin Test Market Attractiveness Analysis, by Patient Type, 2023-2031
Figure 33: North America Fecal Calprotectin Test Market Value Share Analysis, by Assay Type, 2022 and 2031
Figure 34: North America Fecal Calprotectin Test Market Attractiveness Analysis, by Assay Type, 2023-2031
Figure 35: North America Fecal Calprotectin Test Market Value Share Analysis, by Indication, 2022 and 2031
Figure 36: North America Fecal Calprotectin Test Market Attractiveness Analysis, by Indication, 2023-2031
Figure 37: North America Fecal Calprotectin Test Market Value Share Analysis, by End-user, 2022 and 2031
Figure 38: North America Fecal Calprotectin Test Market Attractiveness Analysis, by End-user, 2023-2031
Figure 39: Europe Fecal Calprotectin Test Market Value (US$ Mn) Forecast, 2017-2031
Figure 40: Europe Fecal Calprotectin Test Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 41: Europe Fecal Calprotectin Test Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 42: Europe Fecal Calprotectin Test Market Value Share Analysis, by Patient Type, 2022 and 2031
Figure 43: Europe Fecal Calprotectin Test Market Attractiveness Analysis, by Patient Type, 2023-2031
Figure 44: Europe Fecal Calprotectin Test Market Value Share Analysis, by Assay Type, 2022 and 2031
Figure 45: Europe Fecal Calprotectin Test Market Attractiveness Analysis, by Assay Type, 2023-2031
Figure 46: Europe Fecal Calprotectin Test Market Value Share Analysis, by Indication, 2022 and 2031
Figure 47: Europe Fecal Calprotectin Test Market Attractiveness Analysis, by Indication, 2023-2031
Figure 48: Europe Fecal Calprotectin Test Market Value Share Analysis, by End-user, 2022 and 2031
Figure 49: Europe Fecal Calprotectin Test Market Attractiveness Analysis, by End-user, 2023-2031
Figure 50: Asia Pacific Fecal Calprotectin Test Market Value (US$ Mn) Forecast, 2017-2031
Figure 51: Asia Pacific Fecal Calprotectin Test Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 52: Asia Pacific Fecal Calprotectin Test Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 53: Asia Pacific Fecal Calprotectin Test Market Value Share Analysis, by Patient Type, 2022 and 2031
Figure 54: Asia Pacific Fecal Calprotectin Test Market Attractiveness Analysis, by Patient Type, 2023-2031
Figure 55: Asia Pacific Fecal Calprotectin Test Market Value Share Analysis, by Assay Type, 2022 and 2031
Figure 56: Asia Pacific Fecal Calprotectin Test Market Attractiveness Analysis, by Assay Type, 2023-2031
Figure 57: Asia Pacific Fecal Calprotectin Test Market Value Share Analysis, by Indication, 2022 and 2031
Figure 58: Asia Pacific Fecal Calprotectin Test Market Attractiveness Analysis, by Indication, 2023-2031
Figure 51: Asia Pacific Fecal Calprotectin Test Market Value Share Analysis, by End-user, 2022 and 2031
Figure 60: Asia Pacific Fecal Calprotectin Test Market Attractiveness Analysis, by End-user, 2023-2031
Figure 61: Latin America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, 2017-2031
Figure 62: Latin America Fecal Calprotectin Test Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 63: Latin America Fecal Calprotectin Test Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 64: Latin America Fecal Calprotectin Test Market Value Share Analysis, by Patient Type, 2022 and 2031
Figure 65: Latin America Fecal Calprotectin Test Market Attractiveness Analysis, by Patient Type, 2023-2031
Figure 66: Latin America Fecal Calprotectin Test Market Value Share Analysis, by Assay Type, 2022 and 2031
Figure 67: Latin America Fecal Calprotectin Test Market Attractiveness Analysis, by Assay Type, 2023-2031
Figure 68: Latin America Fecal Calprotectin Test Market Value Share Analysis, by Indication, 2022 and 2031
Figure 69: Latin America Fecal Calprotectin Test Market Attractiveness Analysis, by Indication, 2023-2031
Figure 70: Latin America Fecal Calprotectin Test Market Value Share Analysis, by End-user, 2022 and 2031
Figure 71: Latin America Fecal Calprotectin Test Market Attractiveness Analysis, by End-user, 2023-2031
Figure 72: Middle East & Africa Fecal Calprotectin Test Market Value (US$ Mn) Forecast, 2017-2031
Figure 73: Middle East & Africa Fecal Calprotectin Test Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 74: Middle East & Africa Fecal Calprotectin Test Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 75: Middle East & Africa Fecal Calprotectin Test Market Value Share Analysis, by Patient Type, 2022 and 2031
Figure 76: Middle East & Africa Fecal Calprotectin Test Market Attractiveness Analysis, by Patient Type, 2023-2031
Figure 77: Middle East & Africa Fecal Calprotectin Test Market Value Share Analysis, by Assay Type, 2022 and 2031
Figure 78: Middle East & Africa Fecal Calprotectin Test Market Attractiveness Analysis, by Assay Type, 2023-2031
Figure 79: Middle East & Africa Fecal Calprotectin Test Market Value Share Analysis, by Indication, 2022 and 2031
Figure 80: Middle East & Africa Fecal Calprotectin Test Market Attractiveness Analysis, by Indication, 2023-2031
Figure 81: Middle East & Africa Fecal Calprotectin Test Market Value Share Analysis, by End-user, 2022 and 2031
Figure 82: Middle East & Africa Fecal Calprotectin Test Market Attractiveness Analysis, by End-user, 2023-2031
Figure 83: Global Fecal Calprotectin Test Market Share, by Company, 2022
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Fecal Calprotectin Test Market
